Fluroxan 25 mg/ml (IV Injection or Infusion)
250 mg vial: ৳ 60.00
Medicine Details
Category | Details |
---|---|
Generic | Fluorouracil |
Company | Beacon pharmaceuticals plc |
Indications
- Carcinoma of the colon or rectum
- Carcinoma of the stomach and exocrine pancreas
- Carcinoma of the liver
- Carcinoma of the breast
- Carcinoma of the bladder
- Carcinoma of the lung
- Epithelial ovarian carcinoma
- Cervical carcinoma
Pharmacology
- Conversion of fluorouracil into active 5-fluorodeoxyuridine monophosphate (FdUMP)
- Inhibition of thymidylate kinase enzyme
- Formation of stable complex with folate cofactor N-5, 10-methylene tetrahydrofolate
- Incorporation into RNA
- Effect mainly on proliferative phase cells
Dosage & Administration
- Intravenous rapid bolus injection
- Slow infusion with dextrose 5% solution
- Palliative management schedule
- Poor risk patient and inadequate nutritional state schedule
- Maintenance therapy schedules
- Usual adult and pediatric doses
- Intra-arterial infusion
- Combination with radiation and other anticancer drugs
Interaction
- Pre-treatment with cimetidine leading to increased plasma concentrations
Contraindications
- Severely debilitated patients
- Patients with bone marrow suppression
- Pregnant or breastfeeding women
- Patients without malignant illnesses
Side Effects
- Potentially life-threatening effects
- Cardiac effects
- Hematological effects
- Neurological effects
- Allergic reactions
- Decreased bone marrow function
- Hand-foot syndrome
- Severe vomiting and diarrhea
- Temporary hair loss
- Conjunctivitis
Pregnancy & Lactation
- Contraindicated throughout pregnancy
- Risk of teratogenesis in first trimester
- Inhibition of DNA, RNA, and protein synthesis in nursing mothers
Precautions & Warnings
- Highly toxic with narrow margin of safety
- Supervision required for therapeutic response
- Discontinuation signs of toxicity
- Dose limitations for leucopenia, thrombocytopenia, stomatitis, and severe diarrhea
Use in Special Populations
- No dosage recommendations for neonates
- Safety and effectiveness not established in children
- No special precautions for the elderly
Overdose Effects
- No specific antidote
- Treatment consists of supportive care
- Qualitatively similar to side effects
Reconstitution
- Handling by special, trained personnel
- Preparation in designated room
- Prohibition of smoking, eating, and drinking
- Required equipment for handling
- Skin and mucous membrane contact precautions
- Pregnant women warning
- Disposal of contaminated waste by incineration
Storage Conditions
- Store in original carton
- Not exceeding 25℃
- Protect from light
Related Brands
- 5 FU PhaRes 25 mg/ml (IV Injection or Infusion) - pharma-resources
- Fluracil 25 mg/ml (IV Injection or Infusion) - drug-international-ltd
- Drucil 25 mg/ml (IV Injection or Infusion) - healthcare-pharmaceuticals-ltd
- Flurotor 25 mg/ml (IV Injection or Infusion) - eskayef-pharmaceuticals-ltd
- R-FU 25 mg/ml (IV Injection or Infusion) - renata-limited